Aronne 2024 — SURMOUNT-4 (Tirzepatide Withdrawal/Regain)

JAMA·January 2, 2024

Louis J. Aronne, Naveed Sattar, Deborah B. Horn, Harold E. Bays, Sean Wharton

Summary

After 20.9% mean weight loss during lead-in, continued tirzepatide produced additional 5.5% loss while placebo group regained 14.0% (difference -19.4%). Withdrawal led to substantial regain.

Study Details

Study Design

Phase 3 randomized withdrawal

Indication

Obesity/overweight + comorbidity

Intervention

MTD continuation vs placebo switch

Species

Human

Sample Size

670 subjects

Risk of Bias Assessment

Sponsor-funded